Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ.

Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4.

2.

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.

Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M.

Nat Med. 2019 Apr;25(4):620-627. doi: 10.1038/s41591-019-0367-9. Epub 2019 Mar 4. Erratum in: Nat Med. 2019 Mar 27;:.

PMID:
30833748
3.

The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation.

Loncle C, Molejon MI, Lac S, Tellechea JI, Lomberk G, Gramatica L, Fernandez Zapico MF, Dusetti N, Urrutia R, Iovanna JL.

Cell Death Dis. 2016 Jul 14;7:e2295. doi: 10.1038/cddis.2016.202.

4.

Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.

Sun Y, Peng W, He W, Luo M, Chang G, Shen J, Zhao X, Hu Y.

J Exp Clin Cancer Res. 2018 Jul 24;37(1):166. doi: 10.1186/s13046-018-0818-z.

5.

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.

Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, Zhang Y, Han X, Liu S, Cheng K, Zhao Y, Shi J, Guo J, Hao J, Ren H, Nie G.

Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30.

PMID:
28576749
6.

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF.

Nature. 2014 Oct 30;514(7524):628-32. doi: 10.1038/nature13611. Epub 2014 Aug 10.

7.

KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.

Yang K, Li Y, Lian G, Lin H, Shang C, Zeng L, Chen S, Li J, Huang C, Huang K, Chen Y.

Int J Cancer. 2018 Jun 1;142(11):2323-2334. doi: 10.1002/ijc.31248. Epub 2018 Jan 21.

8.

Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.

Eng CH, Wang Z, Tkach D, Toral-Barza L, Ugwonali S, Liu S, Fitzgerald SL, George E, Frias E, Cochran N, De Jesus R, McAllister G, Hoffman GR, Bray K, Lemon L, Lucas J, Fantin VR, Abraham RT, Murphy LO, Nyfeler B.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):182-7. doi: 10.1073/pnas.1515617113. Epub 2015 Dec 17.

9.

KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.

Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC.

Mol Cancer Res. 2012 Sep;10(9):1228-39. Epub 2012 Aug 7.

10.

CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.

Purohit A, Varney M, Rachagani S, Ouellette MM, Batra SK, Singh RK.

Oncotarget. 2016 Feb 9;7(6):7280-96. doi: 10.18632/oncotarget.6906.

11.

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.

Ischenko I, Petrenko O, Hayman MJ.

Oncotarget. 2015 Jun 30;6(18):15814-27.

12.

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H.

Clin Cancer Res. 2011 May 1;17(9):2744-56. doi: 10.1158/1078-0432.CCR-10-2214. Epub 2011 Mar 8.

13.

Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.

Papademetrio DL, Lompardía SL, Simunovich T, Costantino S, Mihalez CY, Cavaliere V, Álvarez É.

Target Oncol. 2016 Apr;11(2):183-95. doi: 10.1007/s11523-015-0388-3.

PMID:
26373299
14.

Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism.

Cho YR, Lee JH, Kim JH, Lee SY, Yoo S, Jung MK, Kim SJ, Yoo HJ, Pack CG, Rho JK, Son J.

Mol Oncol. 2018 Jun;12(7):1203-1215. doi: 10.1002/1878-0261.12324. Epub 2018 Jun 11.

15.

Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells.

Chen PY, Muzumdar MD, Dorans KJ, Robbins R, Bhutkar A, Del Rosario A, Mertins P, Qiao J, Schafer AC, Gertler F, Carr S, Jacks T.

Cancer Res. 2018 Feb 15;78(4):985-1002. doi: 10.1158/0008-5472.CAN-17-2129. Epub 2017 Dec 26.

16.

Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.

Kopp JL, Dubois CL, Schaeffer DF, Samani A, Taghizadeh F, Cowan RW, Rhim AD, Stiles BL, Valasek M, Sander M.

Gastroenterology. 2018 Apr;154(5):1509-1523.e5. doi: 10.1053/j.gastro.2017.12.007. Epub 2017 Dec 19.

17.

Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.

Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.

Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13.

PMID:
25683115
18.

Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.

Kochetkova EY, Blinova GI, Bystrova OA, Martynova MG, Pospelov VA, Pospelova TV.

Aging (Albany NY). 2017 Nov 14;9(11):2352-2375. doi: 10.18632/aging.101325.

19.

A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.

Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S, Behler N, Irmler M, Beckers J, Friess H, Erkan M, Siveke JT, Tannapfel A, Hahn SA, Theis FJ, Esposito I, Kleeff J, Michalski CW.

Gut. 2016 Apr;65(4):647-57. doi: 10.1136/gutjnl-2014-307616. Epub 2015 Jan 19.

PMID:
25601637
20.

Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.

Thakur PC, Miller-Ocuin JL, Nguyen K, Matsuda R, Singhi AD, Zeh HJ, Bahary N.

J Transl Med. 2018 Jul 9;16(1):190. doi: 10.1186/s12967-018-1562-z.

Supplemental Content

Support Center